<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200691</url>
  </required_header>
  <id_info>
    <org_study_id>HangzhouCH09</org_study_id>
    <nct_id>NCT03200691</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hangzhou Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy and safety of radiation therapy&#xD;
      combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with&#xD;
      resectable esophageal squamous cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">August 10, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate</measure>
    <time_frame>2-4 weeks after completion of radiotherapy</time_frame>
    <description>the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of adverse events and the degree of each adverse events according to the NCI CTCAE 4.0 criteria.</measure>
    <time_frame>6 months</time_frame>
    <description>From the date of randomization to 6 months after esophagectomy. An expected average of 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Esophageal Diseases</condition>
  <arm_group>
    <arm_group_label>Nimotuzumab with radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.&#xD;
SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.&#xD;
After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-DCRT or IMRT radiation</intervention_name>
    <description>Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.</description>
    <arm_group_label>Nimotuzumab with radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-1 antibody SHR-1210</intervention_name>
    <description>SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.</description>
    <arm_group_label>Nimotuzumab with radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have histologically confirmed esophageal squamous cell carcinoma without&#xD;
             prior treatments including surgery, chemotherapy, radiotherapy, and targeting&#xD;
             treatment.&#xD;
&#xD;
          2. With resectable disease of primary tumor in middle or lower thoracic esophagus and&#xD;
             clinical stage Ⅱa-Ⅲ.&#xD;
&#xD;
          3. age:18-75 years, male or female.&#xD;
&#xD;
          4. Can provide either a newly obtained or archival tumor tissue sample.&#xD;
&#xD;
          5. ECOG 0-1.&#xD;
&#xD;
          6. Life expectancy of greater than 12 weeks.&#xD;
&#xD;
          7. Without serious system dysfunction and could tolerate radiotherapy.&#xD;
&#xD;
          8. Patients must have normal marrow function with a hemoglobin (HGB) of ≥90g/L, an white&#xD;
             blood cell (WBC) counts of ≥4.0×109/L，a neutrophil count of ≥2.0×109/L, , a platelet&#xD;
             count of ≥100×109/L, a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL), a&#xD;
             creatinine (Cr) of ≤ 1.5 UNL, alanine aminotransferase (ALAT) and aspartate&#xD;
             aminotransferase (ASAT) of ≤2.5 UNL.&#xD;
&#xD;
          9. Patients must have normal electrocardiogram results and no history of congestive heart&#xD;
             failure.&#xD;
&#xD;
         10. Women of childbearing age should voluntarily take contraceptive measures.&#xD;
&#xD;
         11. Without drug addition&#xD;
&#xD;
         12. Patients must be with good compliance and agree to accept follow-up of disease&#xD;
             progression and adverse events&#xD;
&#xD;
         13. Patients must give written informed consent signed voluntarily by patients themselves&#xD;
             or their supervisors witted by doctors.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have or are currently undergoing additional chemotherapy, radiation&#xD;
             therapy, targeted therapy or immunotherapy.&#xD;
&#xD;
          2. With unresectable disease including any T4b or M1 disease&#xD;
&#xD;
          3. Complete obstruction of the esophagus, or patients who have the potential to develop&#xD;
             perforation&#xD;
&#xD;
          4. Other malignancy within 5 years prior to entry into the study, expect for curatively&#xD;
             treated basal cell and squamous cell carcinoma of the skin and/or curatively resected&#xD;
             in-situ cervical and/or breast cancers.&#xD;
&#xD;
          5. Known central nervous system (CNS) metastases.&#xD;
&#xD;
          6. Subjects with any active autoimmune disease or history of autoimmune disease.&#xD;
&#xD;
          7. Uncontrolled clinically significant heart disease, including but not limited to the&#xD;
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial&#xD;
             infarction within the past 1 year; (4) clinically significant supraventricular&#xD;
             arrhythmia or ventricular arrhythmia requirement for treatment or intervention;&#xD;
&#xD;
          8. Active infection or an unexplained fever &gt; 38.5°C during screening or before the first&#xD;
             scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion&#xD;
             of the investigator);&#xD;
&#xD;
          9. History of Interstitial Pneumonia or active non-infectious pneumonitis.&#xD;
&#xD;
         10. Known Human Immunodeficiency Virus (HIV) infection、active Hepatitis B or Hepatitis C.&#xD;
&#xD;
         11. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) agent.&#xD;
&#xD;
         12. Known history of hypersensitivity to macromolecular protein preparation or any&#xD;
             components of the SHR-1210 formulation.&#xD;
&#xD;
         13. Concurrent medical condition requiring the use of cortisol (&gt;10mg/day Prednisone or&#xD;
             equivalent dose) or other systematic immunosuppressive medications within 14 days&#xD;
             before the study treatment. Except: inhalation or topical corticosteroids. Doses &gt; 10&#xD;
             mg/day prednisone orequivalent for replacement therapy.&#xD;
&#xD;
         14. Received a live vaccine within 4 weeks of the first dose of study medication.&#xD;
&#xD;
         15. Pregnancy or breast feeding.&#xD;
&#xD;
         16. Decision of unsuitableness by principal investigator or physician-in-charge.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shixiu wu, MD</last_name>
    <phone>+8657186826086</phone>
    <email>wushixiu@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hangzhou Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shixiu Wu, MD</last_name>
      <phone>+8657186826086</phone>
      <email>wushixiu@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hangzhou Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Shixiu Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal Squamous Cell Carcinoma</keyword>
  <keyword>PD-1</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

